SCHEMBL3320134

SCHEMBL3320134

COC(=O)c1cccc(CN2CCN(C)CC2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.53
ACHE P22303 1/20 0.53
PARP1 P09874 1/20 0.46
CHKA P35790 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.44
FAAH O00519 1/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
CXCR4 P61073 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HTT P42858 1/20 0.40
CYP1A2 P05177 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2C19 P33261 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RECQL P46063 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31721289 1.00 BCHE (0.53) BCHEACHEPARP1CHKAMRGPRX4
SCHEMBL17805293 0.91 BCHE (0.47) BCHEACHEPARP1CHKAMRGPRX4
SCHEMBL31186159 0.89 BCHE (0.53) BCHEACHEPARP1CHKAMRGPRX4
SCHEMBL465875 0.89 BCHE (0.53) BCHEACHEPARP1MRGPRX4ALDH1A1
SCHEMBL22166986 0.87 CXCR4 (0.52) BCHEACHEPARP1MRGPRX4FAAH
SCHEMBL9278258 0.87 BCHE (0.49) BCHEACHEPARP1MRGPRX4FAAH
SCHEMBL19600507 0.86 BCHE (0.44) BCHEACHEPARP1MRGPRX4ALDH1A1
SCHEMBL30323664 0.86 BCHE (0.44) BCHEACHEPARP1CHKAFAAH
SCHEMBL20671488 0.86 BCHE (0.48) BCHEACHEPARP1MRGPRX4FAAH
SCHEMBL22167005 0.85 CXCR4 (0.61) BCHEACHEPARP1MRGPRX4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105652-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED 2010-04-29 US disclosed
US-20100105652-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED 2010-04-29 US disclosed
US-20100105652-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED 2010-04-29 US disclosed
EP-2118106-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
EP-2028182-A1 Cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-02-25 EP disclosed
EP-2028182-A1 Cysteine protease inhibitors GLAXO GROUP LIMITED (GB) 2009-02-25 EP disclosed
WO-2008107368-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107368-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105652-A1 PURINES AS CYSTEINE PROTEASE INHIBITORS CPN1, SERPINB1, PNP BCHE 575/4885ACHE 1434/4885PARP1 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.